46 related articles for article (PubMed ID: 10388073)
21. FDG-PET/CT and parathyroid carcinoma: Review of literature and illustrative case series.
Evangelista L; Sorgato N; Torresan F; Boschin IM; Pennelli G; Saladini G; Piotto A; Rubello D; Pelizzo MR
World J Clin Oncol; 2011 Oct; 2(10):348-54. PubMed ID: 22022662
[TBL] [Abstract][Full Text] [Related]
22. Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors.
Mankoff DA; Dehdashti F; Shields AF
Neoplasia; 2000; 2(1-2):71-88. PubMed ID: 10933070
[TBL] [Abstract][Full Text] [Related]
23. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
Wu ZJ; Zhang YX; Wei H; Jia Q
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
[TBL] [Abstract][Full Text] [Related]
24. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.
Dimitrakopoulou-Strauss A; Strauss L
Hell J Nucl Med; 2006; 9(1):10-21. PubMed ID: 16617388
[TBL] [Abstract][Full Text] [Related]
25. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
26. Noninvasive diagnosis of solitary pulmonary lesions in cancer patients based on 2-fluoro-2-deoxy-D-glucose avidity on positron emission tomography/computed tomography.
Bar-Shalom R; Kagna O; Israel O; Guralnik L
Cancer; 2008 Dec; 113(11):3213-21. PubMed ID: 18924145
[TBL] [Abstract][Full Text] [Related]
27. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
Metser U; Even-Sapir E
Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
[TBL] [Abstract][Full Text] [Related]
28. Positron Emission Tomography: Current Role for Diagnosis and Therapy Monitoring in Oncology.
Strauss LG
Oncologist; 1997; 2(6):381-388. PubMed ID: 10388073
[TBL] [Abstract][Full Text] [Related]
29. PET/CT for the staging and follow-up of patients with malignancies.
Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
[TBL] [Abstract][Full Text] [Related]
30. FDG-PET in the clinical management of Hodgkin lymphoma.
Hutchings M; Eigtved AI; Specht L
Crit Rev Oncol Hematol; 2004 Oct; 52(1):19-32. PubMed ID: 15363464
[TBL] [Abstract][Full Text] [Related]
31. Assessing tumor response to therapy.
Weber WA
J Nucl Med; 2009 May; 50 Suppl 1():1S-10S. PubMed ID: 19380403
[TBL] [Abstract][Full Text] [Related]
32. Current molecular imaging positron emitting radiotracers in oncology.
Zhu A; Shim H
Nucl Med Mol Imaging; 2011 Mar; 45(1):1-14. PubMed ID: 24899972
[TBL] [Abstract][Full Text] [Related]
33. State-Of-The-Art and Recent Advances in Quantification for Therapeutic Follow-Up in Oncology Using PET.
Carlier T; Bailly C
Front Med (Lausanne); 2015; 2():18. PubMed ID: 26090365
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
